Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593222 | 0.92 | JAK2 (0.34) | BACE1ACKR3SCN1ASCN8AKCNH2 | |
| SCHEMBL13031027 | 0.89 | ACKR3 (0.39) | BACE1ACKR3KCNH2MCHR1KAT2B | |
| Trifluoroacetic Acid SCHEMBL3479657 | 0.88 | GPR6 (0.34) | BACE1ACKR3KCNH2MCHR1FAAH | |
| SCHEMBL592322 | 0.87 | PRKAA2 (0.35) | BACE1ACKR3KCNH2MCHR1KAT2B | |
| SCHEMBL594333 | 0.87 | FAAH (0.35) | BACE1KCNH2MCHR1KAT2BFAAH | |
| SCHEMBL5478973 | 0.87 | KCNH2 (0.38) | BACE1ACKR3KCNH2MCHR1KAT2B | |
| SCHEMBL10183012 | 0.86 | BACE1 (0.34) | BACE1ACKR3KCNH2MCHR1KAT2B | |
| SCHEMBL593414 | 0.86 | POLB (0.34) | BACE1ACKR3SCN1ASCN8AKCNH2 | |
| SCHEMBL593859 | 0.86 | BACE1 (0.35) | BACE1ACKR3KCNH2MCHR1KAT2B | |
| SCHEMBL593705 | 0.86 | BACE1 (0.36) | BACE1ACKR3SCN1ASCN8AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885ACKR3 4450/4885SCN1A 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.